Novel blood-based proteomic signatures across multiple neurodegenerative diseases

Product:

CNS Disease Panel 120, Inflammation Panel 250

Topic:

Neurology

Disease Area:

Alzheimer's Disease

Sample Type:

Serum

Topic/Product:

CNS Disease Panel 120, Inflammation Panel 250

Disease Area:

Alzheimer's Disease

Sample Type:

Serum

Abstract

INTRODUCTION: Blood-based biomarkers have the potential to support early and accurate diagnosis of neurodegenerative diseases, which is sensitive to molecular pathology and predictive of outcome. We evaluated a novel multiplex proteomic method in people with diverse neurodegenerative diseases. METHODS: Serum from people with Alzheimer’s disease (N=36), Lewy body dementia (N=34), frontotemporal dementia (N=36) and progressive supranuclear palsy (N=36) and age-matched controls (N=30) was analysed with the NUcleic acid Linked Immuno-Sandwich Assay (NULISA) central nervous system panel (~120 analytes) and inflammation panel (250 analytes). Biomarkers were compared across groups and included as predictors of survival. RESULTS: The NULISA panels demonstrated high sensitivity and reliability for detecting multiple biomarkers across neurodegenerative disorders. There were condition-specific proteomic biomarkers, while NfL, CRH, CD276 and S100A12 were significant transdiagnostic outcome predictors. DISCUSSION: The sensitive NULISA multiplex approach supports differential diagnosis and target identification, with prognostically informative dementia-related biomarkers.

Authors & Affiliations

Robert Durcan1, Amanda Heslegrave2, Peter Swann3, Julia Goddard1,4, Leonidas Chouliaras 3, Alexander G Murley1, George Savulich3, W Richard Bevan-Jones3, Owen Swann2, Nicholas J Ashton5,6,7,8, Kaj Blennow5,9, William McEwan4, Henrik Zetterberg2,5,9,10,11,12, James B Rowe1,13, John T O’Brien3, Maura Malpetti1,4*

University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 0SZ, UK
UK Dementia Research Institute at UCL, London, WC1N 6BG, UK
Department of Psychiatry, University of Cambridge, Cambridge, CB2 0QQ, UK
UK Dementia Research Institute at University of Cambridge, Cambridge CB2 0XY, UK
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden
Wallenberg Centre for Molecular Medicine, University of Gothenburg, Gothenburg, S-413 45, Sweden
Banner Alzheimer’s Institute and University of Arizona, Phoenix, AZ, USA
Banner Sun Health Research Institute, Sun City, AZ 85351, USA
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, S-431 80, Sweden
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 6BG, UK
Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA
Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.